Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.

doi:10.1016/J.BMC.2005.10.050

Paper

Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.

Published Mar 15, 2006 · M. Ohno, Yoichiro Tanaka, M. Miyamoto

Bioorganic & medicinal chemistry

Q2 SJR score

21

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

The novel 3,4-dihydro-2H-benzo[1,4]oxazin-8-yloxyacetic acid derivatives show potential as dual-acting agents that block the TXA2 receptor and activate the PGI2 receptor, offering a promising treatment for anti-thrombotic and cardiovascular fields

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.

Sign up to use Study Snapshot

References

PET study of the neuroprotective effect of TRA-418, an antiplatelet agent, in a monkey model of stroke.

TRA-418, an antiplatelet agent, shows neuroprotective action in a primate model of stroke, as demonstrated by reduced cerebral damage and increased cerebral metabolic rate of oxygen after reperfusion.

Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.

The novel series of benzofurans show potential as dual-acting antithrombotic agents by blocking thromboxane A2 receptor and activating prostacyclin receptor, offering potential for novel treatments without hypotensive side effects.

Effects of TRA‐418, a novel TP‐receptor antagonist, and IP‐receptor agonist, on human platelet activation and aggregation

TRA-418 is a more effective antiplatelet agent than TP-receptor antagonists or IP-receptor agonists alone, with a different inhibitory profile on P-selectin expression compared to abciximab.

TRA‐418, a novel compound having both thromboxane A2 receptor antagonistic and prostaglandin I2 receptor agonistic activities: its antiplatelet effects in human and animal platelets

TRA-418 has both thromboxane A2 receptor antagonistic and prostaglandin I2 receptor agonistic activities, effectively inhibiting platelet aggregation in human and animal platelets without significant blood pressure or heart rate changes.

FK506 attenuates early ischemic neuronal death in a monkey model of stroke.

FK506 effectively reduces early ischemic neuronal death in a monkey model of stroke, with a therapeutic time window of at least 3 hours after onset.

Citations